BR112020015915A8 - Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer - Google Patents
Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncerInfo
- Publication number
- BR112020015915A8 BR112020015915A8 BR112020015915A BR112020015915A BR112020015915A8 BR 112020015915 A8 BR112020015915 A8 BR 112020015915A8 BR 112020015915 A BR112020015915 A BR 112020015915A BR 112020015915 A BR112020015915 A BR 112020015915A BR 112020015915 A8 BR112020015915 A8 BR 112020015915A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- antigen
- patient
- cancer
- kit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862630038P | 2018-02-13 | 2018-02-13 | |
| US62/630,038 | 2018-02-13 | ||
| US201862732828P | 2018-09-18 | 2018-09-18 | |
| US62/732,828 | 2018-09-18 | ||
| US201862740741P | 2018-10-03 | 2018-10-03 | |
| US62/740,741 | 2018-10-03 | ||
| PCT/US2019/017188 WO2019160755A1 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112020015915A2 BR112020015915A2 (pt) | 2020-12-15 |
| BR112020015915A8 true BR112020015915A8 (pt) | 2023-01-31 |
Family
ID=67620098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020015915A BR112020015915A8 (pt) | 2018-02-13 | 2019-02-08 | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210047409A1 (https=) |
| EP (1) | EP3752193A4 (https=) |
| JP (2) | JP2021513540A (https=) |
| KR (1) | KR20200119845A (https=) |
| CN (2) | CN111727056A (https=) |
| AU (2) | AU2019222517A1 (https=) |
| BR (1) | BR112020015915A8 (https=) |
| CA (1) | CA3090996A1 (https=) |
| MA (1) | MA51844A (https=) |
| MX (1) | MX2020008446A (https=) |
| WO (1) | WO2019160755A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| WO2020185722A2 (en) * | 2019-03-13 | 2020-09-17 | Merck Sharp & Dohme Corp. | Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents |
| CN113244385A (zh) * | 2020-02-07 | 2021-08-13 | 上海君实生物医药科技股份有限公司 | 抗pd-1抗体在治疗恶性肿瘤中的用途 |
| US20230118596A1 (en) * | 2020-03-05 | 2023-04-20 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically accpetable salt thereof |
| EP4114863A4 (en) * | 2020-03-05 | 2024-04-24 | Merck Sharp & Dohme LLC | METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY |
| WO2021213523A1 (zh) * | 2020-04-24 | 2021-10-28 | 信达生物制药(苏州)有限公司 | 抗pd-1抗体和抗ctla-4抗体的组合在预防或治疗癌症中的用途 |
| TW202305009A (zh) * | 2021-04-08 | 2023-02-01 | 美商默沙東有限責任公司 | 以皮下投予抗pd1抗體治療癌症之方法 |
| IL310201A (en) * | 2021-07-19 | 2024-03-01 | Regeneron Pharma | Combination of inhibitor-control inhibitor and oncolytic virus for cancer treatment |
| JP2024540152A (ja) * | 2021-10-29 | 2024-10-31 | オンコシーフォー、インク． | 抗ｃｔｌａ－４抗体投与レジメン |
| CN113933520B (zh) * | 2021-11-15 | 2023-06-20 | 邹灵龙 | 一种通用型抗体药血药浓度检测的单克隆抗体试剂组合、检测方法和试剂盒 |
| US20250376525A1 (en) * | 2022-06-28 | 2025-12-11 | Qilu Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising mixed antibody of anti-ctla4 and anti-pd1 and therapeutic use thereof |
| EP4583981A2 (en) * | 2022-09-09 | 2025-07-16 | Adagene Pte. Ltd. | Activatable anti-ctla4 antibodies for treating cancer |
| CN118767127A (zh) * | 2023-04-10 | 2024-10-15 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体的医药用途 |
| CN121816195A (zh) * | 2023-08-21 | 2026-04-07 | 艾吉纳斯公司 | 使用ctla-4抑制剂和pd-1抑制剂的组合治疗结直肠癌的方法 |
| TW202511295A (zh) * | 2023-08-31 | 2025-03-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Ｃｔｌａ４／ｔｉｇｉｔ結合蛋白及其醫藥用途 |
| WO2026021409A1 (zh) * | 2024-07-22 | 2026-01-29 | 宜明昂科生物医药技术（上海）股份有限公司 | 靶向ctla-4、pd-l1和vegf的肿瘤联合疗法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212422B1 (en) * | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| DK2439273T3 (da) * | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) * | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| JP2018515474A (ja) * | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| EP3322731B1 (en) * | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
| US20180222989A1 (en) * | 2015-08-04 | 2018-08-09 | Glaxosmithkline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
| US20180230431A1 (en) * | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
| ES2986067T3 (es) * | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| US10358496B2 (en) * | 2016-03-01 | 2019-07-23 | Ralf Kleef | Low dose immune checkpoint blockade in metastatic cancer |
| ES2954139T3 (es) * | 2016-06-02 | 2023-11-20 | Bristol Myers Squibb Co | Bloqueo de PD-1 con nivolumab en el linfoma de Hodgkin refractario |
| CN109476753A (zh) * | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗肿瘤的方法的抗-pd-1抗体 |
| JP2019517512A (ja) * | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| JP2020518598A (ja) * | 2017-05-02 | 2020-06-25 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 単独およびプログラム死受容体１（ｐｄ−１）抗体と組み合わされた抗ｃｔｌａ４抗体の安定な製剤、ならびにその使用方法 |
-
2019
- 2019-02-08 JP JP2020542952A patent/JP2021513540A/ja active Pending
- 2019-02-08 AU AU2019222517A patent/AU2019222517A1/en not_active Abandoned
- 2019-02-08 CA CA3090996A patent/CA3090996A1/en active Pending
- 2019-02-08 BR BR112020015915A patent/BR112020015915A8/pt unknown
- 2019-02-08 MX MX2020008446A patent/MX2020008446A/es unknown
- 2019-02-08 CN CN201980013384.1A patent/CN111727056A/zh active Pending
- 2019-02-08 WO PCT/US2019/017188 patent/WO2019160755A1/en not_active Ceased
- 2019-02-08 MA MA051844A patent/MA51844A/fr unknown
- 2019-02-08 CN CN202510115562.9A patent/CN119792515A/zh active Pending
- 2019-02-08 KR KR1020207026005A patent/KR20200119845A/ko not_active Withdrawn
- 2019-02-08 EP EP19754385.3A patent/EP3752193A4/en active Pending
- 2019-02-08 US US16/966,988 patent/US20210047409A1/en active Pending
-
2023
- 2023-07-26 AU AU2023208115A patent/AU2023208115A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000161A patent/JP2024038250A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN119792515A (zh) | 2025-04-11 |
| JP2021513540A (ja) | 2021-05-27 |
| JP2024038250A (ja) | 2024-03-19 |
| AU2023208115A1 (en) | 2024-01-18 |
| EP3752193A4 (en) | 2022-02-23 |
| CN111727056A (zh) | 2020-09-29 |
| BR112020015915A2 (pt) | 2020-12-15 |
| MA51844A (fr) | 2021-05-19 |
| WO2019160755A1 (en) | 2019-08-22 |
| RU2020129075A (ru) | 2022-03-14 |
| US20210047409A1 (en) | 2021-02-18 |
| EP3752193A1 (en) | 2020-12-23 |
| MX2020008446A (es) | 2020-09-28 |
| CA3090996A1 (en) | 2019-08-22 |
| AU2019222517A1 (en) | 2020-08-13 |
| KR20200119845A (ko) | 2020-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020015915A8 (pt) | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| BR112022008858A2 (pt) | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer | |
| BR112018001640A2 (pt) | combinação de antagonista da pd-1 com um inibidor de egfr | |
| BR112016029492A2 (pt) | método para tratamento de linfoma não hodgkin | |
| MX2018003594A (es) | Anticuerpo anti-garp. | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| BR112018000212A2 (pt) | uso combinado de anticorpos anti pd-1 e anti m-csf no tratamento de câncer | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| DOP2012000246A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112022002579A2 (pt) | Anticorpos contra ilt2 e uso dos mesmos | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| BR112014018728A8 (pt) | Compostos de purinonas como inibidores de quinase | |
| BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
| BR112015026006A8 (pt) | composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
| CY1122689T1 (el) | Παραγωγα πυραζολιου χρησιμα ως αναστολεις της πρωτεϊνης ενεργοποιησης της 5-λιποξυγενασης (flap) | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201591773A1 (ru) | Макроциклические ингибиторы rip2-киназы | |
| BR112019011350A2 (pt) | terapia de combinação | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |